1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in European Union, November 2019

Cancer Analysis & Statistics in European Union, November 2019

Customer Support

Talk to Ahmad

+1 718 618 4302

Publication dates

  • All
    • Since 2019

All regions

data types

1-30 of 34 reports

Cyramza

Cyramza

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewCyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Nexavar

Nexavar

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewNexavar (sorafenib; Bayer/Amgen) is an orally available, multi-targeted tyrosine kinase inhibitor that is directed against several targets, including CRAF, BRAF, RET, KIT, FMS-like tyrosine ...

  • Industries : Pathology, Cancer, Therapy
  • Countries : United States, Japan, European Union
Tecentriq

Tecentriq

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewTecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Opdivo

Opdivo

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewOpdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Lenvima

Lenvima

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewLenvima (lenvatinib; Eisai/Merck and Co) is an orally available small molecule inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Keytruda

Keytruda

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewKeytruda (pembrolizumab; Merck and Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Stivarga

Stivarga

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewStivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently approved for the treatment of previously treated hepatocellular carcinoma patients. It ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Cabometyx

Cabometyx

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewCabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Imfinzi

Imfinzi

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewImfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), ...

  • Industries : Pathology, Cancer
  • Countries : European Union, Japan, United States
Afinitor

Afinitor

  • $ 10000
  • Industry report
  • March 2019

Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Sutent

Sutent

  • $ 10000
  • Industry report
  • March 2019

Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth facto ...

  • Industries : Cancer, Therapy, Pathology
  • Countries : United States, Japan, European Union
Votrient

Votrient

  • $ 10000
  • Industry report
  • March 2019

Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Avastin

Avastin

  • $ 10000
  • Industry report
  • March 2019

Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Inlyta

Inlyta

  • $ 10000
  • Industry report
  • March 2019

Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1.

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Torisel

Torisel

  • $ 10000
  • Industry report
  • March 2019

Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
CB-839

CB-839

  • $ 10000
  • Industry report
  • March 2019

Drug OverviewCancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine ...

  • Industries : Cancer, Therapy, Pathology, Oncology
  • Countries : United States, Japan, European Union
Renal cell cancer (RCC) disease forecast and market analysis to 2038

Renal cell cancer (RCC) disease forecast and market analysis to 2038

  • $ 22000
  • Industry report
  • March 2019

DISEASE OVERVIEWRenal cell carcinoma (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Imbruvica

Imbruvica

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewImbruvica (ibrutinib; AbbVie/Johnson and Johnson) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BTK is part of the B-cell receptor signaling pathway, which promotes ...

  • Industries : Cancer, Therapy, Pathology
  • Countries : United States, Japan, European Union
Zanubrutinib

Zanubrutinib

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewZanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK), developed to be more selective with less off-target effects than Imbruvica (ibrutinib; AbbVie/Johnson ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Copiktra

Copiktra

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewCopiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme. The PI3K-delta ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Zydelig

Zydelig

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewZydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in decreased ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Kymriah

Kymriah

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewKymriah (tisagenlecleucel; Novartis) is a cluster of differentiation (CD)19-targeted genetically modified autologous T-cell immunotherapy, comprised of a murine single-chain antibody fragment ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : United States, European Union, Japan
Gazyva

Gazyva

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewGazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union, Japan
Aliqopa

Aliqopa

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewAliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial fo ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States, Japan, European Union
Venclexta

Venclexta

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewVenclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins. This family of proteins is responsible for the regulation of cell death by eithe ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Rituxan

Rituxan

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewRituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo) is a murine/human chimeric cluster of differentiation (CD)20-targeted monoclonal antibody that is indicated for the treatment of a numbe ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : United States, European Union, Japan
Treanda/Bendeka

Treanda/Bendeka

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewTreanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent. The exact mechanism of action of the drug is still not fully known, but it is a mechlorethamine derivative ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Ublituximab

Ublituximab

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewUblituximab (TG Therapeutics/LFB Biotechnologies) is an anti-CD20 monoclonal antibody, currently in late-stage trials across a range of hematological and neurological indications. CD20 is ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States, European Union
Betalutin

Betalutin

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewBetalutin is a first-in-class antibody-radionucleotide conjugate targeted to CD37, an alternative to CD20, which is widely targeted in non-Hodgkin’s lymphoma. CD37 is highly expressed in ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

NHL: Follicular Lymphoma Forecast and Market Analysis (FL) to 2026

  • $ 22000
  • Industry report
  • January 2019

Disease OverviewFollicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts fo ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on